Table 2 Clinical and laboratory characteristics at baseline in 103 participants with severe COVID-19 randomized to treatment with convalescent plasma versus placebo.
CCP | Placebo | Total | ||||
|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | ||||
Total | 52 (50.5%) | 51 (49.5%) | 103 (100%) | |||
BOSCIa score at enrolment | ||||||
4 | 40 (76.9%) | 42 (82.4%) | 82 (79.6%) | |||
5 | 12 (23.1%) | 9 (17.6%) | 21 (20.4%) | |||
Co-morbiditiesb | ||||||
Chronic Kidney disease | 2 (3.8%) | 1 (2%) | 3 (2.9%) | |||
Diabetes | 25 (48.1%) | 15 (29.4%) | 40 (38.8%) | |||
Hypertension | 28 (53.8%) | 28 (54.9%) | 56 (54.4%) | |||
Obesity | 24 (46.2%) | 25 (49%) | 49 (47.6%) | |||
Cardiovascular disease | 1 (1.9%) | 2 (3.9%) | 3 (2.9%) | |||
Cancer | 0 (0%) | 2 (3.9%) | 2 (1.9%) | |||
Chronic pulmonary disease | 2 (3.8%) | 2 (3.9%) | 4 (3.9%) | |||
Concomitant medication | ||||||
Antibiotic | 14 (26.9%) | 11 (21.6%) | 25 (24.3%) | |||
Enoxaparin sodium | 48 (92.3%) | 50 (98%) | 98 (95.1%) | |||
Therapeutic dose | 38 (71.2%) | 36 (72%) | (%) | |||
Prophylactic dose | 10 (20.8%) | 14 (28%) | (%) | |||
Inotropes | 1 (1.9%) | 2 (3.9%) | 3 (2.9%) | |||
Steroids (Dexamethasone/prednisone) | 50 (96.2%) | 47 (92.2%) | 97 (94.2%) | |||
n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | |
|---|---|---|---|---|---|---|
Average days from symptom onset to | ||||||
Hospitalisation | 52 | 5 (3–7) | 51 | 5 (3.5–9.5) | 103 | 5 (3–8) |
Enrolment | 52 | 8 (6–10.25) | 51 | 8 (6–11) | 103 | 8 (6–11) |
Transfusion | 52 | 9 (6–11) | 51 | 9 (7–12) | 103 | 9 (6–11) |
Baseline clinical measurements | ||||||
Pulse (beats/min) | 52 | 85 (74–99) | 50 | 87 (77–95) | 102 | 86 (75–95) |
Respiratory rate (breaths/min) | 52 | 26 (22–30) | 51 | 28 (22–32) | 103 | 28 (22–32) |
Lowest SpO2 prior to starting O2 (%) | 50 | 85.5 (82–88) | 51 | 86 (78–89) | 101 | 86 (80–88) |
PaO2 (kPa) | 36 | 10.3 (8.0–14.0) | 35 | 9.2 (6.0–13.9) | 71 | 9.3 (7.1–14.0) |
Baseline laboratory measurements | ||||||
Creatinine clearance (mL/min) | 43 | 86.6 (61.0–106.0) | 45 | 90.2 (82.3–104.8) | 88 | 88.9 (73.2–104.8) |
Ferritin (μg/L) | 46 | 454.5 (161–776) | 45 | 495.0 (263–1177) | 91 | 495 (213–883) |
d-Dimer (μg/mL) | 42 | 0.5 (0.3–1.7) | 43 | 0.5 (0.3–1.2) | 85 | 0.5 (0.3–1.4) |
Haemoglobin (g/dL) | 45 | 12.9 (11.5–13.9) | 47 | 13.1 (12.1–14.6) | 92 | 13.1 (11.8–14.0) |
Absolute white cell count (× 109/L) | 45 | 12.1 (10.4–15.5) | 48 | 9.8 (8.3–14.2) | 93 | 11.29 (8.4–14.7) |
Absolute neutrophil count (× 109/L) | 44 | 10.0 (6.9–12.8) | 47 | 8.0 (6.3–11.1) | 91 | 9.13 (6.74–12.72) |
Platelets (× 109/L) | 45 | 346 (261–423) | 47 | 322 (229–401) | 92 | 339 (257.5–405.5) |
Alanine aminotransferase (ALT) (IU/L) | 41 | 30 (20–48) | 43 | 35 (26–57) | 84 | 31 (23–51) |
C-reactive protein (μg/L) | 44 | 135 (56–202) | 43 | 111 (62–222) | 87 | 122 (57–207) |
Troponin-T (ng/ml) | 41 | 7 (5–14) | 45 | 9 (6–18) | 86 | 9 (5–17) |
Lactate dehydrogenase (LDH) (U/L) | 37 | 393 (298–459) | 34 | 456 (357–711) | 71 | 415 (314–571) |
